NIIMBL Invests $3 Million in Six Biopharmaceutical Manufacturing Products

The $3 million investment will go towards various projects investigating key product attributes for therapeutic proteins.

The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) announced on Oct. 5th, 2021, that they would invest $3 million in six new biopharmaceutical manufacturing products. Each project will measure glycans through liquid chromatography–mass spectrometry (LC-MS) in some way.

The institutions receiving funding include:

  • North Carolina State University
  • University of Massachusetts
  • University of Georgia
  • University of Michigan
  • University of Delaware
  • Carnegie Mellon University

According to a press release from NIIMBL, each of these projects is specifically geared toward supporting NIIMBL’s Project Call 5.1. The goal of Project Call 5.1 is to perform small group studies that will help determine the variability associated with key product attributes for therapeutic proteins while investing in state-of-the-art analytical instrumentation infrastructure that will be available across the NIIMBL community.

“This project call is a complement to our recent and future project calls and helps to build infrastructure for NIIMBL efforts in one of the important product characterization technologies for our community,” said Chris Roberts, associate institute director at NIIMBL, in the press release. “It was implemented in a similar way to recent rapid project calls from NIIMBL that are in parallel with our multi-stage project calls such as PC5.2 that is expected to be announced later this year.”

Detailed breakdowns of each study can be found at the Project Call 5.1 website.

Source: NIIMBL